Amritt connects VPs of Product Development, Heads of Toxicology, and startup CEOs with rigorously vetted preclinical Indian CROs — at 30–50% lower cost, utilizing our two decades of U.S.–India expertise behind every recommendation.
Several large pharmaceutical companies are quietly saving tens of millions of dollars using pre-clinical CROs in India. Amritt helps you level the playing field — with two decades of U.S.–India experience and expertise behind every recommendation we make.
Three Reasons Companies Choose Pre-Clinical Services From India
India has emerged as a world-class destination for pre-clinical research — not just because it is less expensive, but because it is genuinely competitive on every dimension that matters to drug developers.
Capacity
India is home to a large and growing talent pool of skilled scientists working at pre-clinical CROs — spanning toxicologists, pathologists, veterinarians, and data scientists across 160+ providers.
Cost
World-class pre-clinical work is available at 30–50% lower cost compared to America and Europe, based on work commissioned by Amritt clients since 2022 — without compromising on quality or regulatory acceptability.
Speed
Unlike U.S. and European CROs, which often carry long backlogs, Indian providers can start new studies quickly — a critical advantage for startups managing tight timelines and investor expectations.
Your Expert Guide Through India’s Pre-Clinical Landscape
There are over 160 pre-clinical service providers in India. The difference between the top tier and the rest is significant — in quality systems, regulatory track record, staffing depth, and capacity management. Amritt has reviewed Indian providers across Karnataka, Telangana, Maharashtra, Gujarat, and the Delhi NCR.
VPs of Product Development, Heads of Toxicology, and startup CEOs turn to Amritt for our India expertise and experience. We streamline the task of finding, choosing, and managing the best CRO for your current needs — making the process quick and painless.
Here is what that means in practice:
- We visit CROs personally to meet management and walk through their labs — giving you feet on the street without the cost or jet lag of a long journey across 9–12 time zones
- Our clients are currently using Indian CROs, so we have real-time access to the current state of operations — not outdated intelligence
- We have conducted numerous site visits on behalf of individual clients during ongoing studies — staying involved long after the contract is signed, all the way to study completion
What Amritt Looks for When Evaluating an Indian Pre-Clinical CRO
We call our methodology the Strategic Sourcing Sieve™, a rigorous framework developed over two decades of vendor evaluation. Of the 160+ providers in India, fewer than 20 consistently meet the quality and compliance standards we recommend for regulated studies. Here is what we examine before recommending any provider to a client:
- Accreditations and regulatory track record — Do they hold AAALAC, CPSEA, and other relevant international and local accreditations? Has their work been successfully submitted to the U.S. FDA and EMA? Do they follow Good Laboratory Practice (GLP)?
- In-house scientific staffing — What is the depth and experience of their toxicologists, pathologists, and veterinarians? Is this talent in-house or contracted?
- Ownership and leadership — What is the nature of their ownership structure, and what is the track record of their key executives? (In India, the owners and the key executives might be distinct and different)
- Client mix — What is their balance of large pharma vs. startup clients, and global vs. domestic work? This tells us a great deal about their operational sophistication.
- Capacity and bench strength — How much of their capacity is consumed by their top three to five clients? Do they have genuine availability to serve new clients without compromising ongoing studies?
- Talent acquisition and retention — How do they find, train, and retain good scientists? High turnover is an early warning sign that many Western clients miss.
Not Sure Where to Start? Let’s Talk — Confidentially.
Setting up a pre-clinical study in India is a significant decision. Before you commit to anything, speak directly with Gunjan Bagla — Amritt’s founder and India business expert with 20+ years of experience — for a no-obligation 30-minute call.
Gunjan has helped life sciences companies with their India initiatives since 2006. He is also the author of Doing Business in 21st Century India (Hachette), the definitive guide for Western executives working with Indian partners.
We will tell you honestly whether an Indian CRO makes sense for your current study, your budget, and your regulatory timeline.
No sales pitch. No obligation. Just straight answers. All inquiries strictly confidential.
From First Conversation to Signed CRO Agreement
The most common thing we hear from new clients is some version of this: “We know India could save us money and time, but we have no idea where to start or whom to trust.” That is exactly the problem Amritt was built to solve. Most clients go from first conversation to a signed CRO agreement within 6–10 weeks.
Discovery Call Week 1
A confidential 30-minute conversation with Gunjan Bagla. We learn about your molecule, your study requirements, your timeline, and your budget. You learn whether India is the right fit. If it is not, we will tell you on that first call — no obligation either way.
CRO Longlist Weeks 1–2
Based on your specific needs — species, study type, regulatory pathway, and therapeutic area — Amritt identifies four to six Indian CROs from our vetted network that are credible candidates for your project.
Due Diligence Weeks 2–4
We conduct detailed evaluations of each shortlisted CRO — reviewing accreditations, GLP compliance, FDA submission history, staffing, client mix, and current capacity. Where it matters, Amritt conducts or arranges a personal site visit.
Shortlist and Introduction Weeks 3–5
We present you with a recommended shortlist of two to three CROs with clear reasoning for each recommendation. We facilitate introductions and help you ask the right questions during your own conversations with each provider.
Proposal Review and Selection Weeks 4–8
Amritt helps you evaluate proposals, negotiate scope and pricing, and navigate contract terms — drawing on our experience with how Indian CROs structure their agreements and where there is room to negotiate.
Study Kickoff and Ongoing Support Ongoing
Once your study begins, Amritt remains a resource. We help bridge communication across time zones, translate cultural nuances that could otherwise become friction points, and conduct site visits on your behalf when needed — just as we have done five or more times for several current clients.
What Amritt Clients Say
These are real outcomes from real clients — shared with permission and kept confidential by name.
“The CRO Amritt helped us choose is among the top two pre-clinical service providers I have worked with in my career. Their team has visited the CRO on our behalf five times during our ongoing studies — we could not have managed this relationship without them.”
“Turning to Amritt to help choose among several Indian CROs was one of the best decisions I made as a first-time CEO. The cost savings at high quality extended our angel funding runway through IND-enabling studies and allows us to hit a major value inflection point and focus our subsequent fundraising on a clinical trial.”
Answers to the Questions We Hear Most
If you are evaluating Indian CROs for the first time, these are the questions that matter most — answered directly from our experience.
Provided you work with the right CROs and monitor their work regularly. Indian CRO study data has been successfully submitted to the FDA and EMA by Amritt clients across oncology, rare disease, and anti-infective programs. Amritt’s two decades of cross-cultural communication experience helps in spotting potential issues before they become roadblocks — so you end up with a clean submission package for the next stage of your drug development.
India is 4.5 to 5.5 hours ahead of Western Europe and 8.5 to 12.5 hours ahead of the United States. While Indian CRO staff are typically flexible about taking status calls after hours, Amritt recommends establishing a regular communication cadence with time slots that work for both parties. We also guide CROs to communicate more effectively in writing — being direct, concise, and reducing ambiguity. Where appropriate, we recommend video recordings of key processes that clients can review at their convenience. Amritt staff can also help bridge the gap by communicating directly with the CRO during Indian daytime hours.
Most Indian CROs have reliable access to rats, mice, rabbits, hamsters, and guinea pigs. Beagle dogs, farm pigs, and mini-pigs are available at several CROs. However, due to cultural and regulatory reasons, non-human primates (NHPs) such as cynomolgus monkeys and bovine models are not available at this time. Amritt ensures that any species limitations are clearly understood before a CRO engagement begins.
Today, Indian CROs can handle a very full range of in vivo, in vitro, and in silico studies. They have the equipment, talent, and experience to take on most projects you would send to a typical American, European, or Chinese CRO — including safety pharmacology, toxicology, ADME, efficacy models, and bioanalytical work. Many also have overseas relationships to handle any component they need to outsource. Amritt insists that Indian CROs are fully transparent about any outsourced work before your engagement begins.
Amritt offers two business models, with occasional blending between the two. For startups and early-stage companies managing tight budgets, we sign an agreement where we are compensated by the CROs. Larger companies typically prefer to pay a flat advisory fee to get started, plus a retainer for ongoing monitoring and relationship management. We are happy to discuss which model fits your situation on the first call.
Our Pre-Clinical CRO Evaluation Checklist Includes
Before you engage any CRO in India, know what to look for.
- ✓GLP compliance and FDA audit history
- ✓Species capabilities and study types
- ✓Data integrity and IP protection standards
- ✓Communication across time zones
- ✓Contract terms and pricing benchmarks